1[1]Lazarou J,Pomeranz BH,Corey PN.Incidence of adverse drug reactions in hospitlized patients:ammeta-analysis of prospective studies[J].JAMA,1998,279(15):1200
4[4]Friedman MA,Woodcock J,Lumpkin MM,et al.The safety of newly approved medicines-Dorecent market removals mean there is a problem[J].JAMA,1999,281(18):1728
5[5]Mullins ME,Horowitz BZ,Linden DH,et al.Life-threatening interaction of mibefradilol and β-blockers with dihydropyridine calcium channel blockers[J].JAMA,1998,280(2):157
7[8]Rodrigues AD.Preclinical drug metabolism in the age of high-throughput screening:an industrial perspective[J].Pharm Res,1997,14(11):1504
8[9]Yuan R,Parmelee T,Balian JD,et al.In vitro metabolic interaction studies:Expenience of the food and drug administration[J].Clin Pharmacol Ther,1999,66(1):9
9[10]Department of Health and Human Services,U.S.Food and Drug Administration[S].Drug metabolism/Drug interaction studies in the drug development process:Studies In Vitro.1997,April
10[11]Department of Health Services,Canada[S].Therapeutic products programme guidance document-drug-drug interactions: Studies in vitro and in vivo.2000,September,24
二级参考文献23
1前崎繁文 河野茂.抗真菌药[J].综合临床,1999,48(12):1465-1465.
2Lin J H，Clin Pharmacokinet，1998年，35卷，361页
3Lin J H，Pharmacol Rev，1997年，49卷，403页
4Yasumori T，J Pharmacol Exp Ther，1993年，264卷，89页
5Lin J H，Drug Metab Dispos，1991年，19卷，9页
6Yuan R, Parmelee T, Balian JD, et al. In vitro metabolic interaction studies: Experience of the food and drug administration. Clin Pharmacol Ther, 1999, 66:9.
7Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta- analysis of prospective studies. JAMA,1998,279:1200.
8Friedman MA, Woodcock J, Lumpkin MM, et al. The safety of newly approved medicines - Dorecent market removals mean there is a problem?JAMA, 1999, 281 : 1728.
